The advent of new cancer drugs has been met with both hope and skepticism. On one hand, these drugs offer the potential to extend lives and improve the quality of life for cancer patients. Targeted therapies, such as kinase inhibitors and monoclonal antibodies, have shown great promise in shrinking tumors and prolonging survival. Immunotherapy drugs, which harness the body's own immune system to fight cancer, have also shown remarkable results in certain types of cancer. On the other hand, the high cost of these drugs and the potential for serious side effects raise concerns about their long-term impact on patients and healthcare systems. Careful consideration of the risks and benefits is necessary to ensure that the use of new cancer drugs is truly beneficial and does not lead to unnecessary harm or financial burden.
